AI Terminal
Ambu
Transaction in Own Shares • Dec 29, 2025
3353_rns_2025-12-29_798f3eb2-3067-4bc3-9f88-32a8b0bb036f.pdf
Transaction in Own Shares
Open in ViewerOpens in native device viewer
{0}------------------------------------------------
TRANSACTIONS UNDER AMBU'S SHARE BUYBACK PROGRAM
29.12.2025 10:27:08 CET | Ambu A/S | Changes in company's own shares
On 10 December 2025, Ambu announced a share buyback program (company announcement no. 7 2025/26). The share buyback program is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) (as amended) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbor Regulations
During the program, Ambu will repurchase shares for a total amount of up to DKK 150m from 10 December 2025 until no later than 31 March 2026. The repurchased shares are bought with the aim of completing a share capital decrease as set out in Article 5(2)(a) in MAR.
The following transactions have been made under the program from 22 December to 26 December 2025:
| Number of shares |
Average purchase price, DKK |
Transaction value, DKK |
|
|---|---|---|---|
| Accumulated under the program after last announcement |
389,980 | 86.307 | 33,658,157 |
| 2025.12.22 | 52,200 | 87.1049 | 4,546,876 |
| 2025.12.23 | 1,204 | 87.7500 | 105,651 |
| 2025.12.24 | - | - | - |
| 2025.12.25 | - | - | - |
| 2025.12.26 | - | - | - |
| Accumulated under the program | 443,384 | 86.405 | 38,310,684 |
After the above disclosed transactions DKK 111,689,316 remains to be repurchased. Ambu now owns 3,182,219 treasury shares, corresponding to 1.2% of the share capital.
Contacts
- Anders Hjort, Head of Investor Relations, +45 2892 8881, [email protected]
- Tine Bjørn Schmidt, Director of Corporate Communications, +45 2264 0697, [email protected]
About Ambu A/S
Ever since 1937, Ambu has surpassed expectations with groundbreaking solutions that improve patient care. Millions of patients, clinicians, and health systems worldwide rely on our endoscopy, anesthesia, and patient monitoring solutions for efficiency, safety, and performance. Our ownership of every stage of the product life cycle enables us to work closely with healthcare professionals, maintain a reliable product supply, and uphold full transparency. At our headquarters in Copenhagen, Denmark, and around the world in Europe, North America, and the Asia Pacific, 5,200+ Ambu team members are committed to delivering above and beyond.